NEXAVAR Drug Patent Profile

Which patents cover Nexavar, and when can generic versions of Nexavar launch?

Nexavar is a drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-nine patent family members in thirty-nine countries.

The generic ingredient in NEXAVAR is sorafenib tosylate. There are thirteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the sorafenib tosylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nexavar

A generic version of NEXAVAR was approved as sorafenib tosylate by MYLAN on September 10^th, 2020.

Summary for NEXAVAR

International Patents:	89
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NEXAVAR

Paragraph IV (Patent) Challenges for NEXAVAR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEXAVAR	Tablets	sorafenib tosylate	200 mg	021923	1	2014-02-28

US Patents and Regulatory Information for NEXAVAR

NEXAVAR is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	NEXAVAR	sorafenib tosylate	TABLET;ORAL	021923-001	Dec 20, 2005	AB	RX	Yes	Yes	8,877,933		Y	Y
Bayer Hlthcare	NEXAVAR	sorafenib tosylate	TABLET;ORAL	021923-001	Dec 20, 2005	AB	RX	Yes	Yes	9,737,488		Y

International Patents for NEXAVAR

See the table below for patents covering NEXAVAR around the world.

Country	Patent Number	Title	Estimated Expiration
Cuba	23821	COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UNA DIFENILUREA SUSTITUIDA CON OMEGA-CARBOXIARILO PARA EL TRATAMIENTO DEL CÁNCER
Morocco	26038
China	1341098
Poland	360085

Supplementary Protection Certificates for NEXAVAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1140840	PA 2006 008, C 1140840	Lithuania		PRODUCT NAME: SORAFENIBAS IR FARMACINIU PO?I?RIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
1140840	PA2006008,C1140840	Lithuania		PRODUCT NAME: SORAFENIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
1140840	35/2006	Austria		PRODUCT NAME: SORAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE HIERVON; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
1140840	122006000059	Germany		PRODUCT NAME: SORAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/06/342/001 20060719

NEXAVAR (Sorafenib) Investment Analysis: Market Dynamics, Financial Trajectory, and Strategic Outlook

Last updated: February 3, 2026

---

Executive Summary

NEXAVAR (sorafenib) is an oral multi-kinase inhibitor approved for treating hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and differentiated thyroid carcinoma (DTC). Since its approval by the FDA in 2007, NEXAVAR remains a significant asset within the oncology therapeutic landscape. This analysis evaluates the current market dynamics, growth drivers, competitive positioning, and future financial trajectory of NEXAVAR, emphasizing factors influencing investor decision-making. The therapeutic area’s complexities, patent landscape, competitive environment, and emerging pipeline considerations are critical components shaping its investment outlook.

---

1. Market Overview and Therapeutic Indication Landscape

Indication	2022 Market Size (USD billion)	Predicted CAGR (2022–2028)	Key Drivers
Hepatocellular carcinoma (HCC)	$3.2	7.3%	Rising liver disease prevalence, late diagnosis
Renal cell carcinoma (RCC)	$2.7	6.8%	Increased nephrectomy, advanced diagnostics
Differentiated thyroid carcinoma	$0.8	4.5%	Increasing incidence, improved detection

Sources: MarketsandMarkets[1], Global Data[2]

Current Positioning:

NEXAVAR commands a stable segment share in advanced HCC and RCC, notable for its early entry and broad indication approvals. The global market for sorafenib is characterized by high prevalence rates, significant unmet needs, and a favorable regulatory environment, encouraging sustained use.

2. Market Dynamics: Drivers and Challenges

Drivers

• Expanding Incidence and Diagnosis: Rising prevalence of liver and kidney cancers globally, especially in Asia-Pacific, Latin America, and Sub-Saharan Africa.

• Line of Therapy Expansion: NEXAVAR’s utilization as a first-line and subsequent therapy in HCC and RCC sustains revenue. Notably, evolving treatment algorithms incorporate immune checkpoint inhibitors (ICIs), but NEXAVAR remains a standard in many regions due to cost and regulatory considerations.

• Pricing and Reimbursement Policies: Favorable reimbursement landscapes in key markets, including China and India, bolster access and revenue streams.

• Combination Regimens: Ongoing trials investigating sorafenib with immunotherapies (e.g., atezolizumab) may open new market segments upon approval, potentially extending product lifetime.

Challenges

• Emerging Competition: Approved agents such as lenvatinib, cabozantinib, and immune checkpoint inhibitors (e.g., nivolumab, pembrolizumab) are eroding NEXAVAR’s market share (see Table 1).

• Patent Expirations and Biosimilars: As patent protections weaken, generic competition, especially in key markets (e.g., China, India), pressures revenue.

• Therapeutic Efficacy Limitations: Despite durable responses in some cases, NEXAVAR’s overall survival benefits are moderate, reducing its clinical appeal amid newer therapies.

• Regulatory and Policy Shifts: Price controls, especially in Europe and Asia, could dampen profitability.

Table 1: Competitive Landscape – Main Approved Oncology Agents

Drug Name	Indication(s)	Approval Year	Mechanism of Action	Market Share (2022)	Notable Notes
Sorafenib (NEXAVAR)	HCC, RCC, DTC	2007–2012	Multi-kinase inhibitor	~30% (HCC, 2022)	First-in-class, generic presence
Lenvatinib	HCC, RCC	2018, 2019	VEGFR inhibitor	~25%	Approved in combination with Pembrolizumab
Cabozantinib	RCC, HCC	2016, 2019	MET, VEGFR inhibitor	~15%	Higher efficacy in resistant cases
Nivolumab/Pembrolizumab	Multiple (including RCC, HCC)	2015–2018	PD-1 inhibitors	~20%	Shifting landscape toward immunotherapy

Source: EvaluatePharma[3]

---

3. Financial Trajectory and Revenue Projections

Year	Estimated Global Revenue (USD billion)	Key Assumptions	Notes
2022	$0.9	Stabilized market share in core indications	Post-patent expiry impact begins
2023	$0.8	Slight decline due to competitive pressure and market saturation	Market share erosion continues
2024	$0.75	Entry of biosimilars in key markets	Revenue compression accelerates
2025	$0.65	Adoption of combination therapies and generics	Potential pipeline approvals boost sales
2026	$0.60	Market consolidation, patent expiration impacts	Revenue plateau or slight decline
2027	$0.55	Increased competition, reduced exclusivity	Transition into niche therapy segment

Note: These projections incorporate current trends, regional market dynamics, and pipeline activity, with an acknowledgment of uncertainties introduced by regulatory changes.

---

4. Patent and Regulatory Landscape

Patent Expiry Timeline:

Territory	Original Patent Expiry	Key Patent Challenges	Generic Entry Likelihood
US	2017-2019	Filed patent challenges	High in recent years
Europe	2018	Ongoing patent litigation	Moderate
China	2014-2018	Early generic entry	High

Regulatory Updates and Approvals:

• Major Markets: Approved in >80 countries, including US, EU, Japan, China, India.
• Approved Indications: HCC, RCC, DTC; with expanding uses in combination therapies under clinical trials.
• Clinical Trial Engagement: Active Phase III trials examining combinations with ICIs and novel agents.

5. Strategic Opportunities and Risks

Opportunities	Risks
Growing use of combination with immunotherapies	Competitive patent challenges and biosimilar entry
Expansion into emerging markets	Therapeutic efficacy limitations compared to newer agents
Development of predictive biomarkers for response	Regulatory delays or rejections in pipeline advancements
Potential approval in additional indications	Market saturation and price sensitivity

---

6. Comparative Analysis of Investment Prospects

Aspect	NEXAVAR (Sorafenib)	Newer Agents (e.g., Lenvatinib, Cabozantinib)	Emerging Combinations (e.g., with ICIs)
Patent Status	Expiring or expired	Recent patents, extended exclusivity	Pending, contingent on trial outcomes
Market Share (2022)	~30% in HCC, 25% in RCC	Similar or slightly higher in some regions	Growing potential with positive trial results
Clinical Efficacy	Moderate OS improvement	Higher efficacy in resistant cases	Promising, but require validation
Pricing Power	Moderate	Potentially higher, premium positioning	Variable based on combination therapy approval

---

7. Key Takeaways

• NEXAVAR remains a core oncologic therapy with stable revenues, but faces increasing headwinds from generics and emerging therapies.
• The expansion of combination therapies with immune checkpoint inhibitors offers significant future upside if approved and adopted.
• Patent expirations and biosimilar entries challenge the product’s revenue sustainability, especially in cost-sensitive markets.
• Continuous investment in clinical development, especially in new indications and combination regimens, is critical to prolong the product’s lifecycle.
• Market diversification into emerging markets provides potential growth avenues amid saturation in mature regulatory regions.

---

FAQs

Q1: What are the primary therapeutic indications for NEXAVAR, and how is the market evolving?
A: NEXAVAR is approved for hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and differentiated thyroid carcinoma (DTC). The market is expanding due to increasing incidence rates, but face competitive pressures from newer targeted therapies and immunotherapies.

Q2: How do patent expiries affect NEXAVAR's revenue potential?
A: Patent expirations, notably in key markets like the US and Europe, have resulted in biosimilar entry, reducing pricing power and market share, which erodes revenue streams.

Q3: What competitive agents threaten NEXAVAR’s dominance?
A: Lenvatinib, cabozantinib, and immune checkpoint inhibitors like nivolumab and pembrolizumab are increasingly adopted, offering either superior efficacy or different mechanisms, diminishing NEXAVAR’s relative market share.

Q4: Are combination therapies likely to extend NEXAVAR's market life?
A: Yes. Trials underway investigating NEXAVAR with ICIs (e.g., atezolizumab) could lead to new approved indications, potentially revitalizing its market position if successful.

Q5: What regional factors influence NEXAVAR's market performance?
A: Rapid approvals and expanding market access in China, India, and other emerging economies offer growth opportunities, offsetting stagnation in mature markets.

---

References

[1] MarketsandMarkets. (2022). Oncology Drugs Market.
[2] Global Data. (2022). Oncology Market Reports.
[3] EvaluatePharma. (2022). Market Intelligence Platform.